Autophagy deficiency abolishes liver mitochondrial DNA segregation
Katiane Tostes,Angélica C. dos Santos,Lindomar O. Alves,Luiz R. G. Bechara,Rachel Marascalchi,Carolina H. Macabelli,Mateus P. Grejo,William T. Festuccia,Roberta A. Gottlieb,Julio C. B. Ferreira,Marcos R. Chiaratti
DOI: https://doi.org/10.1080/15548627.2022.2038501
IF: 13.391
2022-02-27
Autophagy
Abstract:Mutations in the mitochondrial genome (mtDNA) are ubiquitous in humans and can lead to a broad spectrum of disorders. However, due to the presence of multiple mtDNA molecules in the cell, co-existence of mutant and wild-type mtDNAs (termed heteroplasmy) can mask disease phenotype unless a threshold of mutant molecules is reached. Importantly, the mutant mtDNA level can change across lifespan as mtDNA segregates in an allele- and cell-specific fashion, potentially leading to disease. Segregation of mtDNA is mainly evident in hepatic cells, resulting in an age-dependent increase of mtDNA variants, including non-synonymous potentially deleterious mutations. Here we modeled mtDNA segregation using a well-established heteroplasmic mouse line with mtDNA of NZB/BINJ and C57BL/6N origin on a C57BL/6N nuclear background. This mouse line showed a pronounced age-dependent NZB mtDNA accumulation in the liver, thus leading to enhanced respiration capacity per mtDNA molecule. Remarkably, liver-specific <i>atg7</i> (autophagy related 7) knockout abolished NZB mtDNA accumulat ion, resulting in close-to-neutral mtDNA segregation through development into adulthood. <i>prkn</i> (parkin RBR E3 ubiquitin protein ligase) knockout also partially prevented NZB mtDNA accumulation in the liver, but to a lesser extent. Hence, we propose that age-related liver mtDNA segregation is a consequence of macroautophagic clearance of the less-fit mtDNA. Considering that NZB/BINJ and C57BL/6N mtDNAs have a level of divergence comparable to that between human Eurasian and African mtDNAs, these findings have potential implications for humans, including the safe use of mitochondrial replacement therapy.<b>Abbreviations:</b> <i>Apob</i>: apolipoprotein B; <i>Atg1</i>: autophagy-related 1; <i>Atg7</i>: autophagy related 7; <i>Atp5a1</i>: ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1; BL6: C57BL/6N mouse strain; <i>BNIP3</i>: BCL2/adenovirus E1B interacting protein 3; FCCP: carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MAP1LC3A: microtubule-associated protein 1 light chain 3 alpha; MAP1LC3B: microtubule-associated protein 1 light chain 3 beta; <i>mt-Atp8</i>: mitochondrially encoded ATP synthase 8; MT-CO1: mitochondrially encoded cytochrome c oxidase I; MT-CO2: mitochondrially encoded cytochrome c oxidase II; <i>mt-Co3</i>: mitochondrially encoded cytochrome c oxidase III; <i>mt-Cytb</i>: mitochondrially encoded cytochrome b; mtDNA: mitochondrial DNA; MUL1: mitochondrial ubiquitin ligase activator of NFKB 1; nDNA: nuclear DNA; <i>Ndufa9</i>: NADH:ubiquinone oxireductase subunit A9; NDUFB8: NADH:ubiquinone oxireductase subunit B8; <i>Nnt</i>: nicotinamide nucleotide transhydrogenase; NZB: NZB/BINJ mouse strain; OXPHOS: oxidative phosphorylation; PINK1: PTEN induced putative kinase 1; <i>Polg2</i>: polymerase (DNA directed), gamma 2, accessory subunit; <i>Ppara</i>: peroxisome proliferator activated receptor alpha; <i>Ppia</i>: peptidylprolyl isomerase A; <i>Prkn</i>: parkin RBR E3 ubiquitin protein ligase; P10: post-natal day 10; P21: post-natal day 21; P100: post-natal day 100; qPCR: quantitative polymerase chain reaction; <i>Rpl19</i>: ribosomal protein L19; <i>Rps18</i>: ribosomal protein S18; SD: standard deviation; SEM: standard error of the mean; SDHB: succinate dehydrogenase complex, subunit B, iron sulfur (Ip); SQSTM1: sequestosome 1; <i>Ssbp1</i>: single-stranded DNA binding protein 1; TFAM: transcription factor A, mitochondrial; <i>Tfb1m</i>: transcription factor B1, mitochondrial; <i>Tfb2m</i>: transcription factor B2, mitochondrial; TOMM20: translocase of outer mitochondrial membrane 20; UQCRC2: ubiquinol cytochrome c reductase core protein 2; WT: wild-type.